On January 19, 2024, STEMCELL Technologies, Canada's largest biotechnology company, announced the acquisition of Propagenix Inc., a Maryland-based biotechnology firm specializing in regenerative medicine technologies. Founded in 2014, Propagenix developed and commercialized unique technologies, including its patented EpiX™ technology, which enables the expansion of adult stem cells from epithelial tissues. In 2017, STEMCELL licensed the rights to EpiX™ for research use applications. The acquisition includes all of Propagenix's assets, intellectual property portfolio, existing business arrangements, and its exclusive license to Conditional Reprogramming technology with Georgetown University. This strategic move allows STEMCELL to develop products based on EpiX™ technology for clinical applications, enhancing its capabilities in regenerative medicine and personalized healthcare